Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Beats Revenue Estimates

分组1 - Arcus Biosciences reported a quarterly loss of $1.27 per share, which was better than the Zacks Consensus Estimate of a loss of $1.33, and compared to a loss of $1 per share a year ago, indicating an earnings surprise of +4.51% [1] - The company posted revenues of $26 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 27.20%, although this was a decrease from year-ago revenues of $48 million [2] - Arcus Biosciences shares have increased approximately 24.9% since the beginning of the year, outperforming the S&P 500's gain of 16.9% [3] 分组2 - The earnings outlook for Arcus Biosciences is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for Arcus Biosciences was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] - The current consensus EPS estimate for the upcoming quarter is -$1.24 on revenues of $20.06 million, and for the current fiscal year, it is -$3.70 on revenues of $228.48 million [7] 分组3 - The Medical - Biomedical and Genetics industry, to which Arcus Biosciences belongs, is currently in the top 37% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this sector [8] - TG Therapeutics, another company in the same industry, is expected to report quarterly earnings of $0.24 per share, reflecting a significant year-over-year change of +1100%, with revenues projected to be $150.66 million, up 79.6% from the previous year [9]